secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-06-23T12:30:46+00:00
Accession:  0001493152-26-029710
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics appoints Dr. Corsee Sanders to board; board expands to six
--------------------------------------------------------------------------------

- Dr. Corsee Sanders appointed as Class III director effective June 17, 2026, term to 2029 annual meeting.
- Board size increased from 5 to 6; Scott Leftwich removed from Audit Committee but remains on board.
- Sanders brings 30+ years pharma experience including Genentech/Roche SVP and Juno/Celgene EVP roles.
- Initial equity award for Sanders deferred pending board assessment of available shares under equity plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/0001493152-26-029710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-029710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer